This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bell, D. W. Articles by Haber, D. A. Search for Related Content PubMed PubMed Citation Articles by Bell, D. W. Articles by Haber, D. A.

Increased Prevalence of EGFR-Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms

Authors' Affiliations: ¹ Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts; ² Department of Biostatistics, Massachusetts General Hospital, Boston, Massachusetts; and ³ Department of Thoracic Surgery, Aichi Cancer Center Research Institute, Nagoya, Japan

Requests for reprints: Daniel A. Haber, Massachusetts General Hospital Cancer Center, Building 149, CNY7, 13th Street, Charlestown, MA 02129. Phone: 617-726-7805; Fax: 617-724-6919; E-mail Haber{at}helix.mgh.harvard.edu.

Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) gene occur in a subset of non–small-cell lung cancer (NSCLC) and are highly predictive of the clinical response to selective EGFR kinase inhibitors. The prevalence of EGFR-mutant NSCLC is appreciably higher in females than in males and in East Asian than in Caucasian populations. We hypothesized that these disparate frequencies may be attributable to underlying genetic modifiers. Given the coincident differences in sex and ethnic origin, we tested allozymatic variants of enzymes involved in estrogen biosynthesis and metabolism, encoded by polymorphic alleles known to differ in frequency between Caucasian and Asian populations, as modifying alleles.

Experimental Design: We genotyped nine polymorphisms in the CYP1A1, CYP17A1, CYP19, HSD17B1, COMT, GSTM1, and GSTT1 genes, in a series of 100 Japanese NSCLCs, selected for equal representation of EGFR wild-type (wt) and EGFR-mutant cases, as well as male and female cases. Associations between polymorphic variants and the EGFR genotype and sex of NSCLC cases were examined using Fisher's exact test of significance.

Results: Only CYP1A1*2C showed a difference in allele frequency that approached statistical significance. Heterozygotes were underrepresented among EGFR-mutant cases compared with EGFR-wt cases (27% versus 47%, P = 0.08), with a concurrent trend toward overrepresentation of CYP1A1*2C^Ile/Ile homozygotes among EGFR-mutant cases as compared with EGFR-wt cases (69% versus 51%, P = 0.13).

Conclusion: Within the power of this study, our findings suggest that the selected polymorphic variants in the estrogen biosynthesis and metabolism pathways are unlikely to be major genetic modifiers of the prevalence of EGFR-mutant NSCLC.

This article has been cited by other articles:

				H. Jiang Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian Perspective Jpn. J. Clin. Oncol., March 1, 2009; 39(3): 137 - 150. [Abstract] [Full Text] [PDF]